Executive Business Director
Description:
The Executive Business Director (EBD) is a senior commercial field leader responsible for driving the successful launch and sustained growth of DBV Technologies' Viaskin® epicutaneous immunotherapy (EPIT) platform across a defined multi-state area. Reporting directly to the Vice President, Sales, the EBD leads a team of Regional Business Directors (RBDs) who in turn manage Regional Account Managers (RAMs) responsible for direct HCP engagement. The EBD is the primary architect of area commercial strategy, translating national direction into locally relevant execution plans while developing field talent, shaping key markets, and delivering measurable business results.
Location: Field-Based (up to 50% travel)
Salary Range: $260K – $325K
Key Responsibilities:
Develop and execute a comprehensive area business plan aligned to national commercial strategy, encompassing territory prioritization, resource allocation, KOL engagement, and quarterly milestone tracking.
Deliver area net sales, market share, and patient start targets by leading, directing, and enabling a team of Regional Business Directors and their Regional Account Managers
Analyze area performance data and field intelligence to identify trends, opportunities, and risks; adjust tactics proactively to maximize commercial impact.
Serve as a senior commercial architect during pre-launch and launch phases; lead area-level market shaping, KOL development, and disease state awareness initiatives.
Identify area-specific market access barriers, competitive dynamics, and adoption challenges; escalate actionable insights to the VP, Sales and commercial operations
Develop deep expertise in peanut allergy epidemiology, EPIT mechanism of action, clinical trial data (EPITOPE, VITESSE), and the competitive landscape to shape strategy and coach the field team.
Partner closely with Medical Science Liaisons (MSLs), Market Access Corporate Account Directors, Marketing, and Patient Services to deliver an integrated, customer-centric approach across the area.
Achieve or exceed quarterly and annual area sales objectives while operating within all compliance and regulatory requirements.
Qualifications:
• Bachelor's degree (B.S. or B.A.) from an accredited four-year college or university; life sciences, business, or healthcare-related field preferred.
• Minimum 10+ years of pharmaceutical or biopharmaceutical commercial experience; allergy/immunology, rare disease, or pediatric specialty experience preferred
• At least 5 years of progressive field sales management
• Demonstrated track record of leading multi-layered field organizations through specialty or biologic product launches.
• Strong business acumen: ability to interpret area-level sales analytics, develop data-driven business plans, and manage resource allocation.
• Deep understanding of specialty pharmacy, biologics access, prior authorization, and hub/patient services models.
• Experience building commercial infrastructure in a start-up or early-stage biopharmaceutical environment is preferred.
• Proficiency with CRM platforms (Veeva preferred) and standard business tools (Microsoft Office, iPad/tablet-based platforms).
• Valid driver's license; ability to travel within area up to 50% of the time, including overnight travel as required.
Behavioral skills:
Curiosity: Keep on exploring uncharted territories. Always ask “why?” and more importantly “why not?”,
Courage: Take smart risks, mentor each other to always do better & be accountable for our choices, our opinions, and our actions,
Collaboration: Teamwork and spirit. Support each other and be equally involved in the achievement of our common goals,
Credibility: Be transparent, follow through and build trust. Educate ourselves about our unique technology.
Department:
Commercial
Locations:
Field Based
Remote status:
Remote
- Department
- Sales & Marketing
- Locations
- US - Warren, NJ
- Remote status
- Fully Remote
- Employment type
- Full-time
About DBV Technologies
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively.
We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need.
This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin.
Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy.
Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.